Anti-Human BCMA/TNFRSF17 Reference Antibody (AMG 224, RUO) (HX959126)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HX959126
Description	Anti-Human CD269/TNFRSF17/BCMA (AMG 224) (HX959126) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	AMG 224
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q02223
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	AMG-224, AMG224, AMG224
Background	Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).
Note	For research use only. Not suitable for clinical or therapeutic use.